Areas of investigation/research focus

Our work focuses on akinetic-rigid Parkinson syndromes:

  • Diseases with pathological aggregation of alpha-synuclein (e.g. Parkinson’s Disease, Dementia with Lewy Bodies, Multisystem Atrophy)
  • Diseases with pathological aggregation of Tau-protein (e.g. Progressive Supranuclear Palsy, Cortico-Basal Degeneration).

The following areas of research have been established in our team:

  • Human genetic studies are performed to identify genetically determined risk factors for neurodegenerative diseases (Fig. 1).
  • Environmental risk factors for neurodegenerative diseases are being determined in experimental studies (Fig. 2).
  • Studies in experimental systems aim at the identification of molecular signals mediating neuronal dysfunction and degeneration (Fig. 3).
  • Cerebral repair processes, e.g. the generation of new neurons in the adult brain, and their potential to counteract neurodegenerative processes are being studied (Fig. 4).
  • Modern imaging modalities are applied to visualize pathological changes in the brains of living patients, aiming at the identification of disease mechanims and markers to ascertain diagnoses and to monitor progression (Fig. 5).
  • On the basis of the clinical and experimental observations, we aim to develop and refine pathophysiological disease concepts allowing to predict promising therapeutic targets, and finally to test these in clinical trials (e.g. Fig. 6).


 more Infos

Figure legends:
Fig. 1: Genetic risk factors: A Manhattan plot showing four newly identified, genetically determined risk factors for the neurodegenerative Tauopathy PSP (threshold P = 5x10-8). Note that the vertical axis is truncated at 10-15, but the P-value for MAPT on chromosome 17p is 10-116. [modified from Höglinger et al., Nature Genetics 2011;43:699-705].
Fig. 2: Environmental risk factors: Molecules which provoke a neurodegenerative Tauopathy in cultured neurons [from Höllerhage et al.; Exp Neurol. 2009;220:133-42].
Fig. 3: Neuronal cell death: Dopaminergic neurons (green) with axonal connection to the striatum (blue) activate a characteristic signal (red) during their demise [from Höglinger et al., Proc Natl Acad Sci U S A. 2007;104:3585–3590.].
Fig. 4: Brain repair: Neuronal stem cells (red) in the subventricular zone of the adult brain are proliferative (green) and embedded in a network of dopaminergic fibers (blue) [modified from Höglinger et al., Nature Neuroscience. 2004;7:726-735].
Fig. 5: Brain imaging: Cerebral PET study of PSP patients showing an upregulation of 5-HT2A receptors in the substantia nigra [from Stamelou et al., Movement Disorders, 2009;24:1170-5].
Fig. 6: Therapy development: Pathophysiological concept and putative therapeutic interventions (red) in Tauopathies [from Stamelou et al., Brain. 2010;133:1578-90].

Key Publications

Adam L Boxer, Jin-Tai Yu, Lawrence I Golbe, Irene Litvan, Anthony E Lang, Günter U Höglinger. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. The Lancet Neurology. 2017 Jun 30; 16:552-563. doi: 10.1016/S1474-4422(17)30157-6
Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders. 2017 May 31; 32:853-864. doi: 10.1002/mds.26987
Julius Bruch, Hong Xu, Thomas W Rösler, Anderson De Andrade, Peer-Hendrik Kuhn, Stefan F Lichtenthaler, Thomas Arzberger, Konstanze F Winklhofer, Ulrich Müller, Günter U Höglinger. PERK activation mitigates tau pathology in vitro and in vivo. EMBO Molecular Medicine. 2017 Feb 28; 9:371-384. doi: 10.15252/emmm.201606664
Höglinger GU, Melhem NM, Dickson DW, Sleiman P M.A, Wang L.S, Klei L, Rademakers R, De Silva R, Litvan I, Riley DE, Van Swieten JC, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics. 2010 Dec 31; 43:699-705. doi: 10.1038/ng.859
Höglinger GU, Rizk P, Muriel MP, Duyckaerts C., Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nature Neuroscience. 2014 Jan 01; 7:726-735.


Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Inform yourself on our website cookie-free. However, we would be pleased if you would allow us to use statistical cookies. Your browser settings regarding cookies are currently as follows:
More information can be found in our Privacy policy.